CardioPhyt™ - Clinical Trials

I Product Info I Ingredients I Recommended Use I Clinical Trials I Research Brief I References




Order this item

Low USA domestic & international shipping

Indication: coronary  and peripheral circulation impairment; impaired myocardial contractility and heart rhythm; high blood pressure; high cholesterol level; vitamin, mineral and microelement deficiency; physical and nervous overload.

Main Actions:improves blood supply to heart and brain, helps maintain healthy cholesterol levels, strengthens blood vessel walls, lowers blood pressure, normalizes the heart rhythm, heart muscle energizer.

Ingredients (per 1 capsule):

Vitamin A (as beta carotene and natural mixed carotenoids (beta-carotene, alpha-carotene, zeaxanthin, cryptoxanthin & lutein)- 2500 IU, Vitamin C (as ascorbyl palmitate) - 110 mg, Vitamin E (as dl-alpha-tocopheryl acetate) - 26 IU, Vitamin B3 (as niacin and niacinamide) - 4 mg, Folic acid - 40 mcg, Vitamin B12 (as cyanocobalamin) - 2 mcg, Magnesium (as magnesium amino acid chelate) - 31.7 mg, Zinc (as zinc amino acid chelate) - 2 mg, Selenium (as selenium amino acid chelate) - 12 mcg, Potassium (as potassium citrate) - 20 mg, Proprietary Blend - 100 mg: Coenzyme Q10, L-Carnitine, Red wine grape extract, Ginkgo biloba (Ginkgo biloba)  leaf extract (50:1) (24 % ginkgo flavone glycosides and 6 % terpene lactones), Odor-controlled garlic (Allium sativum) extract (10,000 ppm allicin), Hawthorn (Crataegus spp) berry concentrate.



CardioPhyt™ - Clinical Trials:

The Department of Biochemistry and Molecular Biology of Bern University in Switzerland conducted a critical and constructive review of epidemiology and supplementation data regarding cardiovascular disease and cancer. Its purpose was to demonstrate that antioxidants entering our body with fruits and vegetables can be vitally important for prophylaxes of cardiovascular diseases and cancer.
The content of vitamins C, E, and carotinoids in blood plasma is inversely proportional to the risk of developing cardiovascular diseases and cancer, the risk is increasing even more with combine deficits of different vitamins.
For optimal health support the balanced intake of vitamins C + E, A, carotinoids and nutrients from vegetables are necessary. (2)

The researchers discovered that low density cholesterol oxidation process is taking place as a result of free radicals impact; it leads to coronary artery atherosclerosis and heart attack. Vitamin E may help prevent or delay coronary heart disease by limiting the oxidation of LDL-cholesterol. (10)
Vitamin E
may also help prevent the formation of blood clots, which could lead to a heart attack. Observational studies have associated lower rates of heart disease with high Vitamin E intake. A study of approximately 90,000 nurses suggested that the incidence of heart disease was 30% to 40% lower among nurses with the highest intake of vitamin E from diet and supplements. Researchers found apparent that the benefit was mainly associated with intake of vitamin E from dietary supplements. High vitamin E intake from food was not associated with significant cardiac risk reduction. (11)
A review of 5,133 Finnish men and women aged 30-69 also suggested that increased dietary intake of vitamin E was associated with decreased mortality (death) from heart disease. (12)

Six clinical trials were conducted to determine the niacin effect in cardiovascular diseases. Clinical trials suggest strong evidence that the use of niacin may prevent and/or treat atherosclerotic cardiovascular disease. The Coronary Drug Project (CDP) was the largest of these trials, and the only one to use niacin monotherapy affecting cardiovascular outcomes: recurrent myocardial infarction and cerebrovascular events were significantly decreased. After a long-term (15 years) follow-up, total mortality was also found to have decreased. 
The other 5 trials used varying combinations of niacin with other pharmacologic agents, examining coronary and total mortality, coronary events, and angiographic progression/regression. Major positive effect was noted in all trials, except for one, where the participants had normal cholesterol level in the beginning.                                              
According to the results of those clinical trials niacin has reduced the incidence of cardiovascular events and stopped the progression of coronary artery lesions. (4)

Vitamin B6, B12 and folic acid deficit can increase serum homocysteine levels. Lowering serum homocysteine levels with folic acid is expected to reduce mortality from ischemic heart disease. (13)

The result of the analysis to determine the positive effect of hawthorn extract in chronic heart failure, demonstrated its effectiveness as a supporting drug for CHF treatment.
Objective: To compare two different therapeutic strategies in the treatment of heart failure stage NYHA II, i.e. a conventional medication and a therapy which also includes hawthorn special extract in addition to chemical-synthetic drugs
Patients and Methods: 952 patients with heart failure (NYHA II) were enrolled in the study. 588 patients received Crataegus special extract either as an add-on therapy or as a monotherapy (Crataegus cohort) and 364 patients received therapy without hawthorn (comparative cohort). 
Results: The clinical symptoms with regard to all parameters investigated showed the same or a more pronounced improvement in the Crataegus cohort in the course of 2 years. After 2 years, the three cardinal symptoms of heart failure - fatigue (p = 0.036), stress dyspnoea (p = 0.020) and palpitations (p = 0.048) - were significantly less marked in the Crataegus cohort than in the comparative cohort.
Conclusion: The data shows a clear benefit for patients with heart failure stage NYHA II treated with Hawthorn extract. The single or add-on administration in addition to a chemical-synthetic medication resulted in objective improvements. (14)